Vimian Group AB (publ) (STO:VIMIAN)

Market Cap	13.62B -33.6%
Revenue (ttm)	4.60B +13.4%
Net Income	338.73M +69.2%
EPS	0.64 +62.1%
Shares Out	529.26M
PE Ratio	39.95
Forward PE	20.12
Dividend	n/a
Ex-Dividend Date	n/a

Volume	178,216
Average Volume	422,990
Open	26.10
Previous Close	26.58
Day's Range	25.58 - 26.56
52-Week Range	24.98 - 46.00
Beta	1.42
RSI	41.98
Earnings Date	Feb 12, 2026

About Vimian Group AB

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the I...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 1,200
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: VIMIAN

Financial Performance

In 2025, Vimian Group AB's revenue was 425.00 million, an increase of 13.39% compared to the previous year's 374.80 million. Earnings were 31.30 million, an increase of 69.19%.

Financial numbers in EUR